Prudential Financial
VIR icon

Prudential Financial’s Vir Biotechnology VIR Stock Holding History

Prudential Financial’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
125,712
+10,310
+9% +$98.1K ﹤0.01% 1573
2026
Q1 		$1.03M Sell
115,402
-166,140
-59% -$1.32M ﹤0.01% 1592
2025
Q4 		$1.7M Buy
281,542
+29,208
+12% +$174K ﹤0.01% 1389
2025
Q3 		$1.44M Sell
252,334
-358,118
-59% -$1.83M ﹤0.01% 1509
2025
Q2 		$3.08M Sell
610,452
-58,337
-9% -$313K ﹤0.01% 1167
2025
Q1 		$4.33M Buy
668,789
+424,220
+173% +$3.77M 0.01% 906
2024
Q4 		$1.8M Sell
244,569
-180,800
-43% -$1.43M ﹤0.01% 1342
2024
Q3 		$3.19M Buy
425,369
+134,300
+46% +$1.17M ﹤0.01% 1221
2024
Q2 		$2.59M Buy
291,069
+148,340
+104% +$1.42M ﹤0.01% 1280
2024
Q1 		$1.45M Sell
142,729
-322,760
-69% -$3.29M ﹤0.01% 1633
2023
Q4 		$4.68M Buy
465,489
+153,420
+49% +$1.4M 0.01% 963
2023
Q3 		$2.92M Buy
312,069
+99,655
+47% +$1.42M ﹤0.01% 1156
2023
Q2 		$5.21M Sell
212,414
-6,638
-3% -$167K 0.01% 883
2023
Q1 		$5.1M Sell
219,052
-39,170
-15% -$1M 0.01% 865
2022
Q4 		$6.54M Sell
258,222
-2,495
-1% -$61.2K 0.01% 769
2022
Q3 		$5.03M Buy
260,717
+114,505
+78% +$2.91M 0.01% 881
2022
Q2 		$3.72M Buy
146,212
+82,555
+130% +$1.93M 0.01% 1045
2022
Q1 		$1.64M Buy
63,657
+52,882
+491% +$1.57M ﹤0.01% 1621
2021
Q4 		$451K Buy
10,775
+4,420
+70% +$173K ﹤0.01% 2240
2021
Q3 		$277K Buy
6,355
+1,530
+32% +$66.2K ﹤0.01% 2355
2021
Q2 		$228K Buy
4,825
+260
+6% +$11.8K ﹤0.01% 2414
2021
Q1 		$234K Buy
+4,565
New +$246K ﹤0.01% 2359

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Prudential Financial's VIR Position: Q2 2026 in Review

Prudential Financial increased its Vir Biotechnology (VIR) stake by 8.9% in Q2 2026, buying an estimated $98.1K and bringing the position to 125,712 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

Prudential Financial first reported a position in VIR in Q1 2021 and has held it in 22 quarters since. The position peaked at $6.54M in Q4 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Prudential Financial held 125,712 shares of Vir Biotechnology worth $1.28M as of Q2 2026.
  • Prudential Financial bought 10,310 Vir Biotechnology shares in Q2 2026, an estimated $98.1K.
  • Vir Biotechnology made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1573 holding.
  • Prudential Financial first reported a position in Vir Biotechnology in Q1 2021 and has held it in 22 quarters since.
  • Prudential Financial's Vir Biotechnology position peaked at $6.54M in Q4 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.